We are live on ! Find out more
MBOT icon

Microbot Medical
MBOT

30 hedge funds and large institutions have $4.66M invested in Microbot Medical in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,124% more capital invested

Capital invested by funds: $381K → $4.66M (+$4.28M)

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

6.57% more ownership

Funds ownership: 7.39% → 13.97% (+6.6%)

3% more funds holding

Funds holding: 29 → 30 (+1)

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

Holders
30
Holders Change
+1
Holders Change %
+3.45%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
6
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.31M
2
Renaissance Technologies
Renaissance Technologies
New York
+$989K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$359K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$205K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$152K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$48.2K
2
SM
Sabby Management
Florida
-$30.4K
3
Citigroup
Citigroup
New York
-$27.2K
4
Citadel Advisors
Citadel Advisors
Florida
-$23K
5
Bank of America
Bank of America
North Carolina
-$4.99K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$1.52M +$989K +127,200 +185%
BlackRock
2
BlackRock
New York
$1.34M +$1.31M +168,763 +3,479%
SM
3
Sabby Management
Florida
$646K -$30.4K -3,910 -4%
Vanguard Group
4
Vanguard Group
Pennsylvania
$358K +$359K +46,177 New
Geode Capital Management
5
Geode Capital Management
Massachusetts
$323K +$152K +19,583 +88%
Bank of New York Mellon
6
Bank of New York Mellon
New York
$204K +$205K +26,324 New
Millennium Management
7
Millennium Management
New York
$128K +$129K +16,530 New
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$103K – – –
Morgan Stanley
9
Morgan Stanley
New York
$28K +$23.1K +2,965 +492%
Royal Bank of Canada
10
Royal Bank of Canada
Ontario, Canada
$5K +$4.81K +619 +61,900%
Wells Fargo
11
Wells Fargo
California
$2K – – –
Fidelity Investments
12
Fidelity Investments
Massachusetts
$2K +$1.55K +199 +19,900%
UBS Group
13
UBS Group
Switzerland
$1K -$48.2K -6,206 -98%
FDCDDQ
14
Federation des caisses Desjardins du Quebec
Quebec, Canada
$31 – – –
RE
15
RBC Europe
United Kingdom
$8 – – –
Citadel Advisors
16
Citadel Advisors
Florida
– -$23K -13,653 Closed
Citigroup
17
Citigroup
New York
– -$27.2K -3,501 -100%
Bank of America
18
Bank of America
North Carolina
– -$4.99K -642 -99%
Barclays
19
Barclays
United Kingdom
– -$3.73K -480 -100%
AG
20
Advisor Group
Arizona
– -$3.63K -467 -100%
Deutsche Bank
21
Deutsche Bank
Germany
– +$777 +100 New

MBOT Hedge Fund Activity: Q1 2019 in Review

30 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Microbot Medical (MBOT) for Q1 2019, worth a combined $4.66M — up 1,124% from $381K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new MBOT positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 6 trimmed.

The largest buyer was BlackRock, adding an estimated $1.31M. The largest seller was UBS Group, cutting an estimated $48.2K.

  • 30 institutional investors held Microbot Medical (MBOT) as of Q1 2019, up from 29 in Q4 2018.
  • Funds reported $4.66M of Microbot Medical stock for Q1 2019, up 1,124% quarter-over-quarter.
  • 4 funds opened new Microbot Medical positions in Q1 2019 and 3 closed out, a net change of +1 holder.
  • The largest Microbot Medical buyer in Q1 2019 was BlackRock, an estimated $1.31M added.
  • The largest Microbot Medical seller in Q1 2019 was UBS Group, an estimated $48.2K sold.

Based on aggregated 13F filings for Q1 2019.